NeuroOne Medical Technologies Corp Dossier
Qualitative Analysis
Business overview
NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) is a clinical-stage medical technology company focused on developing and commercializing thin-film electrode technology platforms. The company's high-definition, minimally invasive devices are designed for continuous electroencephalogram (cEEG) and stereoelectroencephalography (sEEG) recording, brain mapping, and tissue ablation. Its core product families include the Evou0002 Cortical Electrodes, Evou0002 sEEG Electrodes, and the OneRFu0002 Ablation System. These technologies target neurological disorders such as epilepsy, Parkinson's disease, dystonia, essential tremors, and chronic pain. NeuroOne leverages a strategic partnership with Zimmer Biomet, which holds exclusive distribution rights for its sEEG electrodes and the OneRF system for brain applications.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Focusing development efforts on three critical clinical areas: brain (OneRF Ablation System), pain (spinal cord stimulation and basivertebral nerve ablation), and advanced drug delivery (sEEG-based drug delivery system).
Expected impact: Positions the company for major strategic and commercial inflection points, expanding the addressable market beyond diagnostic electrodes into therapeutic ablation and drug delivery.
Leveraging Zimmer Biomet's national and international commercial infrastructure to distribute the OneRF Ablation System for use in the brain, minimizing NeuroOne's SG&A burden.
Expected impact: Drives high-margin product revenue growth. Q1 fiscal 2026 represented the strongest quarter since launch, with nearly 50% of all historical OneRF brain ablations performed in that single quarter.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Provides NeuroOne with global commercial reach and a robust sales network for its Evo electrode technology and OneRF Ablation System in the brain, eliminating the need for a costly direct sales force.
Terms: Under the October 2024 amendment, NeuroOne received an upfront payment of $3.0 million (recognized as license revenue in fiscal 2025) with the potential to earn additional milestone-based payments.